WGO Graded Evidence: Osteoporosis

Level: Clinical Trials: 25 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Denosumab in men receiving androgen-deprivation therapy for prostate cancer. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HALT Prostate Cancer Study Group, N Engl J Med. 2009 Aug 20;361(8):745-55
	Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial, N Engl J Med. 2009 Aug 20;361(8):756-65
	A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. S Henderson, N Hoffman, R Prince, Am J Gastroenterol. 2006 Jan:119-23
	Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. RH Boone, AM Cheung, LM Girlan, EJ Heathcote, Dig Dis Sci. 2006 Jun:1103-12
	A randomized trial of vertebroplasty for osteoporotic spinal fractures. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, Edwards R, Gray LA, Stout L, Owen S, Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH, Jarvik JG, N Engl J Med. 2009 Aug 6;361(6):569-79
	A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, Graves S, Staples MP, Murphy B, N Engl J Med. 2009 Aug 6;361(6):557-68
	Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. F Walther, C Fusch, M Radke, S Beckert, A Findeisen, J Pediatr Gastroenterol Nutr. 2006 Jul:42-51
	Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. H Rautiainen, M Færkkilæ, M Neuvonen, T Sane, AL Karvonen, H Nurmi, P Kærkkæinen, PJ Neuvonen, JT Backman, Aliment Pharmacol Ther. 2006 Dec:1545-52
Supplementary evidence:
	A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. KM Wissing, N Broeders, R Moreno-Reyes, C Gervy, B Stallenberg, D Abramowicz, Transplantation. 2005 Jan 15:108-15
	Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. N Guañabens, A Parés, I Ros, L Alvarez, F Pons, L Caballería, A Monegal, MJ Martínez de Osaba, M Roca, P Peris, J Rodés, Am J Gastroenterol. 2003 Oct:2268-74
	Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. CH Chesnut III, A Skag, C Christiansen, R Recker, JA Stakkestad, A Hoiseth, D Felsenberg, H Huss, J Gilbride, RC Schimmer, PD Delmas, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE), J Bone Miner Res. 2004 Aug:1241-9
	Efficacy and safety of ibandronate given by intravenous injection once every 3 months. S Adami, D Felsenberg, C Christiansen, J Robinson, RS Lorenc, P Mahoney, K Coutant, RC Schimmer, PD Delmas, Bone. 2004 May:881-9
	Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. AZ Lacroix, DS Buist, SK Brenneman, TA Abbott 3rd, Med Care. 2005 Mar:293-302
	Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. R Recker, JA Stakkestad, CH Chesnut 3rd, C Christiansen, A Skag, A Hoiseth, M Ettinger, P Mahoney, RC Schimmer, PD Delmas, Bone. 2004 May:890-9
	Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. MJ Gardner, RH Brophy, D Demetrakopoulos, J Koob, R Hong, A Rana, JT Lin, JM Lane, J Bone Joint Surg Am. 2005 Jan:3-7
	Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. V Abitbol, JY Mary, C Roux, JC Soulé, J Belaiche, JL Dupas, JP Gendre, E Lerebours, S Chaussade, Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID), Aliment Pharmacol Ther. 2002 May:919-27
	Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. D Kendler, AW Kung, Gel-H Fuleihan, JG González González, KA Gaines, N Verbruggen, ME Melton, Maturitas. 2004 Jul 15:243-51
	Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. S Nishiguchi, S Shimoi, H Kurooka, A Tamori, D Habu, T Takeda, S Kubo, J Hepatol. 2001 Oct:543-5
	Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. E Barrett-Connor, JA Cauley, PM Kulkarni, A Sashegyi, DA Cox, MJ Geiger, J Bone Miner Res. 2004 Aug:1270-5
	Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. C Meier, HW Woitge, K Witte, B Lemmer, MJ Seibel, J Bone Miner Res. 2004 Aug:1221-30
	Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid. [No Authors Listed], Prescrire Int. 2005 Feb:5-9
	The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women. S Arrenbrecht, P Caubel, P Garnero, D Felsenberg, Maturitas. 2004 Jul 15:197-207
	Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. C von Tirpitz, J Klaus, M Steinkamp, LC Hofbauer, W Kratzer, R Mason, BO Boehm, G Adler, M Reinshagen, Aliment Pharmacol Ther. 2003 Mar 15:807-16
	Wheat bran fiber supplementation and bone loss among older people. Z Chen, WA Stini, JR Marshall, ME Martínez, JM Guillén-Rodríguez, D Roe, DS Alberts, Nutrition. 2004 Sep:747-51
	YOUTH: decisions and challenges in designing an osteoporosis prevention intervention for teen girls. LL DeBar, C Ritenbaugh, N Vuckovic, VJ Stevens, M Aickin, D Elliot, E Moe, E Orwoll, D Ernst, LM Irving, Prev Med. 2004 Nov:1047-55